A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy
Progress in Cardiovascular Diseases , 06/21/2012
Sherrid MV et al. – Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, authros offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM.